Belite Bio, Inc
NASDAQ · us_market
No AI insight generated yet for this ticker.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 52.0K | $8.29M | 0.01% | New | 2026-03-31 |
| StateStreet | passive | 16.0K | $2.56M | 0.00% | Added+2.0% | 2026-03-31 |
| TRowePrice | fundamental | 281.8K | $44.93K | 0.01% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.77 | — | — |
| 2026-05-20 | -0.64 | -0.68 | -5.78% |
| 2026-03-02 | -0.54 | -0.70 | -30.32% |
| 2025-11-10 | -0.49 | -0.65 | -32.65% |
| 2025-08-11 | -0.42 | -0.50 | -19.76% |
| 2025-05-14 | -0.36 | -0.45 | -23.29% |
| 2025-03-17 | -0.31 | -0.32 | -4.07% |
| 2024-11-12 | -0.30 | -0.28 | +6.67% |
| 2024-08-09 | -0.26 | -0.31 | -19.23% |
| 2024-05-14 | -0.28 | -0.27 | +5.26% |
| 2024-03-12 | -0.30 | -0.24 | +19.33% |
| 2023-11-14 | -0.32 | -0.40 | -25.00% |
| 2023-08-09 | -0.30 | -0.26 | +12.61% |
| 2023-05-10 | -0.23 | -0.33 | -43.48% |
| 2023-03-31 | -0.33 | -0.25 | +24.24% |
| 2022-11-03 | -0.24 | -0.24 | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BLTE | -6.89% | -14.12% | -9.86% | +122.26% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.86% | -9.48% | -6.42% | +109.57% |